This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Adrian Krainer | |
|---|---|
| Name | Adrian Krainer |
| Birth date | 1958 |
| Birth place | Montevideo, Uruguay |
| Fields | Molecular biology; Genetics; Biochemistry |
| Alma mater | University of Uruguay; Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory |
| Known for | Splice-switching antisense oligonucleotides; Nusinersen development; Pre-mRNA splicing research |
| Awards | Lasker~DeBakey Clinical Medical Research Award; Breakthrough Prize in Life Sciences; Warren Alpert Foundation Prize |
Adrian Krainer
Adrian Krainer is a molecular biologist and geneticist noted for pioneering work on pre-mRNA splicing and the development of splice-switching antisense oligonucleotides that led to the FDA approval of nusinersen for spinal muscular atrophy. He has held laboratory and faculty positions at Cold Spring Harbor Laboratory and has collaborated with academic, biopharmaceutical, and clinical institutions worldwide. His research intersects with RNA biology, human genetics, and translational medicine, influencing therapies for hereditary neuromuscular disorders.
Born in Montevideo, Uruguay, Krainer completed early studies before relocating for graduate training. He pursued doctoral work and postdoctoral research at institutions known for molecular genetics, training alongside groups at Cold Spring Harbor Laboratory where leaders in RNA processing and genetic regulation such as James D. Watson and Walter Gilbert had earlier established research traditions. During his formative years he was influenced by research communities associated with the University of Cambridge, Massachusetts Institute of Technology, and Rockefeller University through collaborative exchanges and conferences including meetings of the RNA Society and Cold Spring Harbor Symposia.
Krainer established a laboratory focusing on pre-mRNA splicing, RNA-binding proteins, and antisense technologies. His career includes positions at Cold Spring Harbor Laboratory and interactions with research centers like the National Institutes of Health, Howard Hughes Medical Institute, and academic hospitals engaged in neuromuscular research. He collaborated with investigators at institutions such as Harvard Medical School, Yale School of Medicine, Massachusetts General Hospital, and University of Pennsylvania, and engaged with biotechnology firms and foundations that support translational research, including Ionis Pharmaceuticals, Biogen, and the Muscular Dystrophy Association. Krainer’s laboratory participated in multi-center studies with clinicians from Columbia University Medical Center, Johns Hopkins University, and the University of California system, contributing to clinical development pathways and regulatory submissions to agencies including the Food and Drug Administration and European Medicines Agency.
Krainer’s team made foundational discoveries in spliceosome function, regulatory splicing factors, and the modulation of alternative splicing through antisense oligonucleotides. Key contributions connect to canonical spliceosomal components studied by investigators at EMBL, Max Planck Institute, and Cold Spring Harbor Laboratory, and to landmark genetic disorders investigated at Boston Children’s Hospital and Great Ormond Street Hospital. Major achievements include elucidating roles for SR proteins and hnRNPs in splice site selection, characterizing mechanisms of exon skipping and inclusion relevant to Duchenne muscular dystrophy and spinal muscular atrophy, and developing therapeutic strategies translated into clinical practice.
His work directly enabled the development of nusinersen, a splice-modifying antisense oligonucleotide approved for spinal muscular atrophy, through collaborations among academic groups, biotechnology companies, and clinical consortia that included investigators from Karolinska Institutet, University College London, and the Mayo Clinic. Krainer’s research contributed to broader applications of antisense technology, influencing initiatives at institutions such as the Wellcome Sanger Institute, Broad Institute, and Cold Spring Harbor Laboratory’s translational programs, and informing regulatory science at agencies like the National Institutes of Health and European Medicines Agency.
Krainer has received numerous prizes and recognitions from scientific organizations and foundations. Honors include the Lasker~DeBakey Clinical Medical Research Award, the Breakthrough Prize in Life Sciences, the Warren Alpert Foundation Prize, and awards from professional societies such as the American Society for Biochemistry and Molecular Biology and the RNA Society. He has been elected to esteemed bodies including the National Academy of Sciences, the American Academy of Arts and Sciences, and international academies associated with the Royal Society, EMBO, and the Institute of Medicine. Additional recognition came through lectureships and prizes from institutions such as Columbia University, Rockefeller University, and Harvard Medical School.
Krainer’s professional activities intersect with clinical advocacy groups and philanthropic organizations focused on rare diseases and neuromuscular disorders, including the Muscular Dystrophy Association and Cure SMA. He has participated in advisory boards and collaborative networks linking academic research at Cold Spring Harbor Laboratory with clinical centers such as Boston Children’s Hospital, Addenbrooke’s Hospital, and Great Ormond Street Hospital. Biographical profiles have appeared in outlets covering biomedical research and innovation ecosystems, and his mentorship has influenced trainees who established independent groups at institutions such as Yale University, University of California San Francisco, and Stanford University.
- Landmark articles on pre-mRNA splicing and splicing factors published in journals including Nature, Science, Cell, EMBO Journal, and Proceedings of the National Academy of Sciences, often in collaboration with researchers from Harvard Medical School, Massachusetts Institute of Technology, Rockefeller University, and EMBL. - Translational reports on antisense oligonucleotide therapies and clinical development of splice-modulating agents appearing in journals such as New England Journal of Medicine, The Lancet, and Nature Medicine, coauthored with clinicians from Boston Children’s Hospital, Columbia University Medical Center, and University College London. - Reviews and perspective pieces on RNA therapeutics, genetic medicine, and spliceosome biology published in Annual Review of Biochemistry and Nature Reviews Genetics, engaging with topics addressed by the RNA Society, Cold Spring Harbor Symposia, and the Broad Institute.
Category:Molecular biologists Category:Geneticists Category:Cold Spring Harbor Laboratory faculty